



## Aflac Cancer Center COG Phase I Clinical Trials

Brain Tumor			
COG ADVLO912	A Phase 1/2 Study of PF-02341066, An Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma (Am 4)	1/11	>12 mo to <21 yr
COG ADVL1013	A Phase I Study of Mk-2206, an AKT inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors or Leukemias	I	>12 mo to <21 yr
COG ADVL1112	A Phase I Study of Imetelstat, a Telomerase Inhibitor, in Children with Refractory or Recurrent Solid Tumors and Lymphomas	I	>12 mo to <21 yr
Leukemia/Lymphoma			
COG ADVLO912	A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma (Am 4)	1/11	>12 mo to <21 yr
COG ADVL1011	A Phase 1 Study of JAK Inhibition (INCB018424) in Children with Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms (Am 2)	1	>12 mo to <21 yr
COG ADVL1013	A Phase I Study of Mk-2206, an AKT inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors or Leukemias	I	>12 mo to <21 yr
COG ADVL1112	A Phase I Study of Imetelstat, a Telomerase Inhibitor, in Children with Refractory or Recurrent Solid Tumors and Lymphomas	1	>12 mo to <21 yr
Solid Tumors			
COG ADVLO912	A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma (Am 4)	1/11	>12 mo to <21 yr
COG ADVL1011	A Phase 1 Study of JAK Inhibition (INCB018424) in Children with Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms (Am 2)	I	>12 mo to <21 yr
COG ADVL1013	A Phase I Study of Mk-2206, an AKT inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors or Leukemias	I	>12 mo to <21 yr
COG ADVL1112	A Phase I Study of Imetelstat, a Telomerase Inhibitor, in Children with Refractory or Recurrent Solid Tumors and Lymphomas	I	>12 mo to <21 yr

## For More Information or to Make a Referral

- Visit our online clinical trials database at <a href="www.choa.org/clinicaltrials">www.choa.org/clinicaltrials</a>
- Contact Sindy Midoro at 404-785-1441 or sindy.midoro@choa.org